G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, especially for those of you who, like us, took an extended break to connect with ancient observances. Now, of course, the time has come to resume the usual routine of meetings, deadlines and the like. So tap your inner zen, grab a cup of stimulation, and dive into the tidbits below. Have a smashing day and, as always, do stay in touch …

The credibility of an expert witness for the U.K. pharmaceuticals industry was shot down by the National Institute for Health and Care Excellence in a legal row over pricing, The Times reports. The cost watchdog dismissed evidence from drug makers as “plainly not independent.” Through their trade group, the companies are seeking an unprecedented judicial review in an attempt to stop NICE from imposing fresh limits on prices for new drugs and reversing changes to the cost assessment of treatments for rare diseases.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy